The pharmaceutical company Stayble Therapeutics has received approval to initiate a clinical phase Ib study with STA363 in patients suffering from chronic disc herniation. In parallel with the disc herniation project, the company is working on completing the phase IIb study in degenerative disc disease, while preparing for future partnerships. With two indications in the portfolio, the company's attractiveness and bargaining power in partnering discussions increase.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/03/stayble-adds-disc-herniation-to-the-pipeline-study-approved/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock-stayble-adds-disc-herniation-to-the-pipeline---study-approved,c3728555

(c) 2023 Cision. All rights reserved., source Press Releases - English